SECOND DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF BERGENBIO'S BGBC020 TRIAL ASSESSING BEMCENTINIB IN COVID-19 PATIENTS
Bergen, Norway, 8[th ]February 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, provides an update on the Company sponsored Phase II clinical trial (BGBC020), assessing the efficacy and safety of bemcentinib for the treatment of hospitalised COVID-19 patients in South Africa and India, following the second meeting of the trial's independent Data Monitoring Committee (iDMC). The iDMC, formed from a group of independent infectious disease clinical experts external to the study,